[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 552
1. Dandapani SV, Eaton M, Thomas CR Jr, Pagnini PG: HIV- positive anal cancer: an update for the clinician. J Gastrointest Oncol; 2010 Sep;1(1):34-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV- positive anal cancer: an update for the clinician.
  • Anal cancer used to be a rare cancer traditionally associated with elderly women.
  • The onslaught of the Human Immunodeficiency Virus (HIV) virus has led to a change in anal cancer demographics.
  • Anal cancer is on the rise in the U.S and the number of anal cases documented has quadrupled in the past 20 yrs correlating with the rise of the HIV epidemic.
  • The incidence of anal cancer is 40 to 80 fold higher in the HIV positive (HIV+) population when compared to the general population (2).
  • As a consequence non AIDS defining cancers such as anal cancer are on the rise.
  • Factors implicated in the etiology of anal cancer in HIV+ patients include (Human papillomavirus) HPV virus status, sexual habits, and a history of smoking.
  • HPV 16 and receptive anal intercourse (RAI) increase the risk of anal cancer by 33% over the general population.
  • In the general population, the rate of anal cancer is approximately 0.9 cases per 100,000.
  • In patients with a history of RAI, the rate approaches 35 cases per 100,000 which is equivalent to the prevalence of cervical cancer (3).
  • Smokers are eight times more likely to develop anal cancer.
  • There has been much discussion about tailoring treatment decisions in HIV+ patients with anal cancer.
  • This review focuses on squamous cell carcinomas of the anal canal which comprise 80 to 90% of all anal cancers diagnosed and highlight key issues in the management of HIV+ anal cancer patients including recent clinical trials.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 1992 Feb;84(2):165-76 [1602515.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Radiat Oncol. 2006;1:29 [16916475.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9 [19203845.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):298-301 [19717198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1425-32 [19744801.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] Diagn Cytopathol. 2010 Jul;38(7):538-46 [19941374.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1413-9 [20231064.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1123-8 [20354531.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1085-6; author reply 1086-7 [20386381.001]
  • [Cites] Hematol Oncol Clin North Am. 2010 Jun;24(3):567-75 [20488354.001]
  • [Cites] Oncology (Williston Park). 2010 Aug;24(9):828, 830-1 [20923036.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72 [12852659.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):891-7 [19502853.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Curr Probl Cancer. 2009 Sep-Oct;33(5):302-26 [20082844.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 22811803.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3397564
  • [Keywords] NOTNLM ; Anal canal / Anal cancer / HIV
  •  go-up   go-down


2. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Veit-Haibach P, Treyer V, Strobel K, Soyka JD, Husmann L, Schaefer NG, Tschopp A, Hany TF: Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging; 2010 Oct;35(5):528-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Forty-six consecutive patients (mean age: 60 (34-82) years; 20 f, 26 m) with known liver lesions (colorectal metastases (n = 34), primary liver cancer (n = 4), breast cancer (n = 3), anal cancer, gastric cancer, esophageal cancer, GIST, duodenal cancer (all: n = 1) who were referred for staging or therapy follow-up by [18F]-Fluoro-2-deoxy-D-glucose-positron-emission-tomography/computed-tomography imaging (FDG-PET/CT) were included.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593563.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


Advertisement
4. Irabor DO, Dongo AE: Anal carcinoma in a tropical low socio-economic population in the new millennium: What has changed? Trop Doct; 2009 Jan;39(1):7-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in a tropical low socio-economic population in the new millennium: What has changed?
  • The paper is a retrospective look at the clinicopathological presentation of carcinoma of the anal canal in a tertiary health institution in Nigeria.
  • Sixty-five patients were diagnosed with anal carcinoma over a five-year period (2002-2006) from a total of 394 patients who had malignancies of the colon, rectum and anus.
  • The male: female ratio was 1.2: 1 showing a slight male predominance; the average age was 48 years; tenesmus, bleeding per rectum and anal pain were the most common presenting features.
  • The most predominant histopathological subtype was adenocarcinoma - a departure from the hitherto squamous cell cancer dominance.
  • [MeSH-major] Adenocarcinoma. Anus Neoplasms. Carcinoma
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Socioeconomic Factors. Tropical Climate. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211411.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Gao L, Zhou F, Li X, Yang Y, Ruan Y, Jin Q: Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One; 2010;5(12):e15256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal HPV infection in HIV-positive men who have sex with men from China.
  • BACKGROUND: Anal HPV infection, which contributes to the development of anal warts and anal cancer, is well known to be common among men who have sex with men (MSM), especially among those HIV positives.
  • However, HIV and anal HPV co-infection among MSM has not been addressed in China.
  • Blood and anal swabs were collected for HIV-1 serological test and HPV genotyping.
  • HIV and anal HPV prevalence were 8.5% and 62.1%, respectively.
  • A strong dose-response relationship was found between HIV seropositivity and multiplicity of HPV genotypes (p<0.001), which is consistent with the observation that anal HPV infection was an independent predictor for HIV infection.
  • CONCLUSIONS: A high prevalence of HIV and anal HPV co-infection was observed in the MSM community in Beijing and Tianjin, China.
  • Anal HPV infection was found to be independently associated with increased HIV seropositivity, which suggests the application of HPV vaccine might be a potential strategy to reduce the acquisition of HIV infection though controlling the prevalence of HPV.
  • [MeSH-major] Anal Canal / virology. Anus Diseases / virology. HIV Infections / complications. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):471-9 [10950374.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):39-47 [15714063.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):248-54 [11463923.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]
  • [Cites] Vaccine. 2006 Mar 30;24 Suppl 1:S1-15 [16406226.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Sex Transm Infect. 2008 Aug;84(4):306-11 [18385223.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):777-82 [18813791.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):965-73 [19239366.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1986-92 [19567510.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):330-5 [19342375.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):354-8 [19351623.001]
  • [Cites] AIDS Educ Prev. 2009 Oct;21(5):430-46 [19842827.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):111-6 [19779357.001]
  • [Cites] J Infect Dis. 2010 Jun 1;201(11):1677-85 [20415595.001]
  • [Cites] Oncology (Williston Park). 2010 Apr 15;24(4):364-9 [20464850.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Sex Transm Dis. 2003 Aug;30(8):639-44 [12897686.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1386-8 [9358136.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] AIDS. 1998 Jul 9;12(10):1177-84 [9677167.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Obstet Gynecol. 2000 Dec;96(6):879-85 [11084171.001]
  • (PMID = 21151900.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2997781
  •  go-up   go-down


6. Doddi S, Singhal T, De Silva C, Smedley F, Sinha P, Leslie M: Small cell carcinoma of the anus: a case report. Cases J; 2009;2:9396
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the anus: a case report.
  • Small cell carcinoma of the anus is a very rare but aggressive tumour.
  • We present a case of a 60-year old lady with small cell carcinoma of the anus.
  • Immunohistochemistry is required to make a diagnosis.
  • Chemotherapy remains the mainstay of treatment for small cell carcinoma of the anus with or without metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1068-76 [17614337.001]
  • [Cites] Histopathology. 2007 Jan;50(1):163-74 [17204029.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3156-8 [15918209.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12):692-3 [18852720.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Surg Today. 2002;32(1):72-4 [11871823.001]
  • [Cites] Surg Today. 1993;23(1):85-8 [8384908.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):635-42 [8026228.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • (PMID = 20076782.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806881
  •  go-up   go-down


7. Pitts MK, Fox C, Willis J, Anderson J: What do gay men know about human papillomavirus? Australian gay men's knowledge and experience of anal cancer screening and human papillomavirus. Sex Transm Dis; 2007 Mar;34(3):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What do gay men know about human papillomavirus? Australian gay men's knowledge and experience of anal cancer screening and human papillomavirus.
  • OBJECTIVE: The objective of this study was to determine levels of experience and knowledge concerning anal dysplasia, anal Pap smear tests, and human papillomavirus (HPV) among gay and other homosexually active men.
  • On a range of measures, it was clear that the men knew very little about anal cancer (19% scored zero on a 12-point knowledge scale) and virtually nothing about HPV (47% scored zero on an 8-point knowledge scale).
  • A total of 55.1% had never heard of an anal Pap smear and 44.8% had ever heard of HPV; 56.4% did not know whether it affected men and/or women.
  • CONCLUSIONS: The test for anal dysplasia is still largely unknown among Australian gay men and they currently have poor sense of personal susceptibility to the disease.
  • [MeSH-major] Anus Neoplasms / prevention & control. Carcinoma in Situ / prevention & control. Health Knowledge, Attitudes, Practice. Homosexuality, Male / psychology. Papillomaviridae. Papillomavirus Infections / prevention & control

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837830.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, Fox T, Esteves F, Landry J, Godette K: PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From March to November 2003, 20 patients with rectal cancer and 3 patients with anal cancer were treated with preoperative or definitive chemoradiation, respectively.
  • For 25% of patients with rectal cancer, PET detected distant metastases and changed overall management.
  • Ten rectal cancer patients underwent surgery.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Rectal Neoplasms / radiography. Rectal Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707268.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Elit L, Voruganti S, Simunovic M: Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. Gynecol Oncol; 2005 Jul;98(1):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature.
  • BACKGROUND: : HIV is associated with a decrease in cellular immunity which allows for persistence of high-risk HPV types and this can predispose the woman to dysplasia or cancer of the gynecologic tract.
  • CASE: : We present a case of Stage 3 vulvar cancer in a 33-year-old HIV positive woman.
  • CONCLUSION: : The optimal treatment of advanced vulvar cancer in HIV positive patients remains unclear given the small number of cases reported in the literature.
  • Lessons from the anal cancer literature may help inform the care of vulvar cancer patients given the comparable high prevalence of this disease in the patients infected with HIV.


10. Karamercan A, Tatlicioglu E, Ferahkose Z: Strangulation of a prolapsed rectal cancer in labor: a case report. J Reprod Med; 2007 Jun;52(6):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strangulation of a prolapsed rectal cancer in labor: a case report.
  • BACKGROUND: Colorectal cancer during pregnancy is uncommon.
  • Delayed diagnosis due to confusing significant lower gastrointestinal symptoms with pregnancy-associated gastrointestinal changes is a common feature.
  • From the increasing intraabdominal pressure during delivery, a tumor can prolapse throu the anus and develop incarceration and strangulation, but that is seen a extremely rarely, CASE: A 33-year-old woman was found to have a prolapsing rectal cancer through the anus during delivery, and it progressed to incarceration, CONCLUSION: Colorectal cancer during pregnancy is rare and mostly localized to the rectum.
  • The choice of surgical procedure is controversial if the preoperative diagnosis is not clear.


11. Ramos-Suzarte M, Pintado AP, Mesa NR, Oliva JP, Iznaga-Escobar N, Aroche LT, Pimentel G, González J, Cordero M, Rodríguezi OT, Crombet RT, Pérez RR: Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II. Cancer Biol Ther; 2007 Jan;6(1):22-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II.
  • Monoclonal antibody (mAb) ior c5 is an IgG1, which recognizes a glycoprotein tumor specific antigen IOR C2 over expressed in the surface of colon and ovarian cancer cells.
  • METHODS: Eighty six patients with colorectal or anal cancer, mean age 57 +/- 13 yrs, were involved in a phase 1/11 multicentric, open clinical trial to assess the ability of Radioimmunoscintigraphy (RIS) with 99mTc- mAb ior c5 to detect those tumors.
  • Seventy-four patients received 1 mg of c5 labeled with 1480-1850 MBq to determinate diagnosis efficacy and safety of murine mAb by intravenously (i.v.) bolus injection (group 1).
  • CONCLUSIONS: Immunoscintigraphy with 99mTc-labeled mAb ior c5 could be a useful procedure for the diagnosis and follow-up of the patients with colorectal tumors, its metastasis and recurrences.
  • [MeSH-major] Antibodies, Monoclonal. Anus Neoplasms / radionuclide imaging. Carcinoma / radionuclide imaging. Colorectal Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224642.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ior c5 monoclonal antibody
  •  go-up   go-down


12. Hayanga AJ: When to test women for human papillomavirus: take this opportunity to screen for anal cancer too. BMJ; 2006 Jan 28;332(7535):237
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When to test women for human papillomavirus: take this opportunity to screen for anal cancer too.
  • [MeSH-major] Anus Neoplasms / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Tumor Virus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis


13. Zbar AP, Shenoy RK, Chiappa A: Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol; 2007;4:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: We report our results of a selective approach to primary direct appositional vaginal repair versus transverse rectus abdominis flap repair (TRAM) in patients with extensive rectal/anal cancer or in cases with primary cancer of cervix, vagina or vulva involving the anal canal and anal sphincters.
  • Exenterative procedures were performed in 2 cases of primary vaginal cancer, following Wertheim hysterectomy for carcinoma of the cervix with recurrence after radiation and in 2 further cases of anal cancer with extensive pelvic recurrence after primary chemoradiation.
  • Fifteen cases are alive on follow-up with no evidence of disease; 2 patients who had recurrent carcinoma of the cervix and who underwent TRAM flap reconstruction, have recurrent disease after 5 and 6 months of follow-up, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):596-601 [15863165.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2229-35 [8918419.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):389-94 [15657636.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):398-403 [15297179.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):424-6 [14760771.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):39-45 [12468340.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1144-50 [12209702.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):239-45; discussion 245-8 [11852339.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):751-65 [6647599.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):542-8 [15882183.001]
  • (PMID = 17214895.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779795
  •  go-up   go-down


14. Sebészeti Szakmai Kollégium: [Position statement of the College of Surgery of Hungary about screening for colorectal cancer]. Orv Hetil; 2008 Nov 16;149(46):2195-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Position statement of the College of Surgery of Hungary about screening for colorectal cancer].
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / prevention & control. Mass Screening / methods. Mass Screening / organization & administration
  • [MeSH-minor] Adult. Aged. Colonoscopy. Early Detection of Cancer. Feces. Humans. Hungary. Middle Aged. Occult Blood. Patient Rights. Societies, Medical. Time Factors


15. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


17. Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM: Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst; 2005 Jun 15;97(12):896-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.
  • BACKGROUND: Infection with human papillomavirus (HPV) is causally linked to the development of anal and cervical cancer.
  • In the United States, the incidence of anal cancer among men who have sex with men (MSM) is higher than the incidence of cervical cancer among women.
  • Anal squamous intraepithelial lesions (ASILs) are anal cancer precursors comprising low-grade squamous intraepithelial lesions (LSILs) and high-grade squamous intraepithelial lesions (HSILs).
  • The prevalence of cervical cancer precursor lesions peaks at around 30 years of age.
  • Anal cytology and behavioral data were obtained.
  • Anal HPV infection status was assessed by polymerase chain reaction.
  • In a multivariable analysis, the risk of LSILs was associated with having more than five male receptive anal sex partners (P = .03), any use of poppers (alkyl nitrites) in the previous 6 months [odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.1 to 2.5; P = .03] or use of injection drugs two or more times per month during the previous 6 months [OR = 19, 95% CI = 1.3 to 277; P = .03], older age at first receptive anal intercourse (P = .004), and infection with a greater number of HPV types (P < .001 for linear trend).
  • The risk of HSILs was associated with any anal HPV infection (OR = 3.2, 95% CI = 1.1 to 9.4; P = .039) and infection with an increasing number of HPV types (P < .001 for linear trend).
  • [MeSH-major] Aging. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Homosexuality, Male. Papillomaviridae. Papillomavirus Infections / epidemiology. Precancerous Conditions / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956651.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / 5 U01 AI46749; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / N01 AI35176; United States / NIAID NIH HHS / AI / N01 AI45200; United States / NIAID NIH HHS / AI / R01 AI 88739; United States / NCI NIH HHS / CA / R01 CA 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NIAID NIH HHS / AI / U01 AI47995; United States / NIAID NIH HHS / AI / U01 AI48016; United States / NIAID NIH HHS / AI / U01 AI48040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Kinjo A, Ogawa K, Iraha S, Tamaki W, Toita T, Kakinohana Y, Samura H, Kinjo I, Nishimaki T, Kuniyoshi Y, Murayama S: [Concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal-report of four cases]. Gan To Kagaku Ryoho; 2008 Mar;35(3):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal-report of four cases].
  • We have treated four Japanese patients with squamous cell carcinoma of the anal canal using concurrent chemoradiotherapy.
  • These four patients have been alive and free of disease (follow-ups of 55, 14, 7 and 5 months, respectively), with excellent function of the anal sphincter after treatment.
  • These results suggest that concurrent chemoradiotherapy is safe and effective for Japanese patients with squamous cell carcinoma of the anal canal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347409.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M: The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol; 2008 Jun;87(3):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.
  • BACKGROUND AND PURPOSE: To investigate acute and late radiotherapy-related adverse events following intensity-modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy of anal cancer.
  • MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for anal squamous cell cancer were evaluated for acute and late radiotherapy-related adverse events.
  • A correlation between the equivalent dose in 2Gy fractions (EQD2) at the wall of anal canal opposite to the tumour and radiation proctitis was observed.
  • CONCLUSIONS: IMRT significantly reduces acute radiotherapy-associated adverse events in patients treated by chemoradiotherapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501454.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


20. Kreuter A, Wieland U, Brockmeyer N: [Anal carcinoma and anal intraepithelial neoplasia in HIV-infections]. J Dtsch Dermatol Ges; 2006 Jul;4(7):611-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal carcinoma and anal intraepithelial neoplasia in HIV-infections].
  • [Transliterated title] Analkarzinom und anale intraepitheliale Neoplasie bei HIV-Infektion.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. HIV Infections / diagnosis. Skin Neoplasms / diagnosis


21. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


22. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J: Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol; 2009 Sep;114(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.
  • OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC).
  • SCAC is more common in women, typically presenting at an older age than gynecologic cancers.
  • The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
  • The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer.
  • Amongst the cases, there were 7 cervical, 3 vulvar and 1 vaginal cancers compared with 5 cervical, 0 vulvar and vaginal cancers in the 3264 controls.
  • Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3).
  • The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
  • CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Genital Neoplasms, Female / epidemiology. Neoplasms, Multiple Primary / epidemiology. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501390.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Gorez E, Staumont G: [Epidermoid anal carcinoma]. Rev Prat; 2008 Oct 31;58(16):1783-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid anal carcinoma].
  • [Transliterated title] Carcinome epidermoïde anal.
  • Epidermoid carcinoma of the anus is a rare cancer, and conventionally affects elderly women.
  • Main predisposing factors are sexually transmitted diseases and particularly human papillomavirus (HPV) infection, variety of sexual partners, smoking, homosexuality, history of uterine cervix cancer, and immunodepression.
  • Warning signs of anal cancer are often non-specific.
  • The evaluation assessment should include lung X-ray, abdominal CT scan, and often pelvis MNR or anal endosonography.
  • First-line treament of anal epidermoid carcinoma is radiotherapy, combined with chemotherapy for extensive forms.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Age Factors. Aged. Anal Canal / pathology. Biopsy. Combined Modality Therapy. Female. Homosexuality, Male. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143150.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The relative roles of immunodeficiency, HIV viral load, and combination antiretroviral therapy (cART) in the onset of individual cancers have rarely been examined.
  • We examined the effect of these factors on the risk of specific cancers in patients infected with HIV-1.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • FINDINGS: Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer.
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • For cervical cancer, we noted a strong effect of current CD4 (RR 0.7 per log(2), 95% CI 0.6-0.8; p=0.0002).
  • The RR of cervical cancer for those receiving cART was 0.5 (0.3-0.9; p=0.03).
  • The risk of anal cancer increased with the time during which the CD4 count was less than 200 cells per microL (1.3 per year, 1.2-1.5; p=0.0001), and viral load was greater than 100 000 copies per mL (1.2 per year, 1.1-1.4, p=0.005).
  • INTERPRETATION: cART would be most beneficial if it restores or maintains CD4 count above 500 cells per microL, thereby indicating an earlier diagnosis of HIV infection and an earlier treatment initiation.
  • Cancer-specific screening programmes need to be assessed in patients with HIV.
  • FUNDING: Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.


25. Mai SK, Welzel G, Haegele V, Wenz F: The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol; 2007;2:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer.
  • BACKGROUND: Smoking is an important risk factor for the development of cancer.
  • We evaluated the effect of smoking during radiochemotherapy on the outcome for patients with anal cancer.
  • METHODS: Sixty-eight patients (34 smokers, 34 non-smokers) treated by radiochemotherapy for anal cancer were analysed.
  • CONCLUSION: Even though our evaluation reached statistical significance only in univariate analysis, we suggest, that the role of smoking during radiochemotherapy for anal cancer should not be ignored.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Smoking / adverse effects

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Carcinogenesis. 1993 Feb;14(2):329-32 [8382117.001]
  • [Cites] FASEB J. 1993 Aug;7(11):1045-51 [8370474.001]
  • [Cites] Rev Med Interne. 1993 May;14(5):340-9 [8235150.001]
  • [Cites] J Cutan Med Surg. 2001 Jul-Aug;5(4):323-8 [11907844.001]
  • [Cites] Head Neck. 2002 Dec;24(12):1031-7 [12454940.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Mutat Res. 2004 Jun 13;560(2):167-72 [15157654.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] JAMA. 1980 Nov 14;244(19):2175-9 [6252357.001]
  • [Cites] Int J Cancer. 1981 Aug 15;28(2):153-6 [7319670.001]
  • [Cites] J Natl Cancer Inst. 1982 Mar;68(3):395-9 [6950166.001]
  • [Cites] Can Med Assoc J. 1982 Oct 15;127(8):727-9 [7139487.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] Clin Exp Immunol. 1985 Aug;61(2):459-66 [2931227.001]
  • [Cites] Cancer. 1989 May 15;63(10):2060-5 [2702575.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4024-9 [2736543.001]
  • [Cites] Int J Colorectal Dis. 1989 Dec;4(4):234-43 [2614221.001]
  • [Cites] FASEB J. 1994 Jun;8(9):654-60 [8005393.001]
  • [Cites] Gynecol Obstet Invest. 1995;39(1):34-8 [7890250.001]
  • [Cites] Gynecol Obstet Invest. 1996;41(4):253-9 [8793496.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • (PMID = 17711570.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2078591
  •  go-up   go-down


26. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


27. Czito BG, Willett CG: Current management of anal canal cancer. Curr Oncol Rep; 2009 May;11(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of anal canal cancer.
  • Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence.
  • At present, RT with 5-FU and mitomycin is the standard of care for anal cancer patients.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1020-2 [16505418.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5281-6 [18024876.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):390-5 [6401588.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1057-63 [16505424.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • (PMID = 19336010.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Number-of-references] 24
  •  go-up   go-down


28. Fox P: Anal cancer screening in men who have sex with men. Curr Opin HIV AIDS; 2009 Jan;4(1):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer screening in men who have sex with men.
  • PURPOSE OF REVIEW: To determine whether current evidence and expert opinion support the routine use of anal cytology and high-resolution anoscopy in men who have sex with men.
  • RECENT FINDINGS: Most recently published guidelines do not recommend routine anal cytology, but anal cancer is undoubtedly a serious and growing problem for HIV-positive patients.
  • Two recent cohort studies have provided data that suggest that the precursor lesion (high-grade squamous intraepithelial lesion) might not be more prevalent in patients on highly active antiretroviral therapy than in historical pre-highly active antiretroviral therapy cohorts or in HIV-negative men who have sex with men.
  • The sensitivity and specificity of anal cytology is poor and adjuncts to cytology such as p16(ink4a) staining and human papillomavirus viral loads might be utilized to further reduce the number of patients requiring high-resolution anoscopy.
  • Despite the burden of high-grade squamous intraepithelial lesion in HIV negative men who have sex with men, anal cancer remains uncommon in this group.
  • SUMMARY: Although routine anal cytology is not advisable for men who have sex with men at present, be they HIV positive or negative, clinicians should be regularly performing digital rectal examination in those at high risk of anal cancer, both to facilitate early detection of anal cancer and in the interests of health promotion.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Homosexuality, Male. Mass Screening
  • [MeSH-minor] Anal Canal / pathology. Antiretroviral Therapy, Highly Active. Biomarkers, Tumor / analysis. Clinical Trials as Topic. Early Detection of Cancer. Epidemiologic Studies. HIV Infections / complications. HIV Infections / drug therapy. Humans. Male. Papillomavirus Infections / diagnosis. Papillomavirus Infections / etiology. Papillomavirus Infections / pathology. Proctoscopy. Sensitivity and Specificity. Viral Load

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19343830.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 25
  •  go-up   go-down


29. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF: Epidemiologic review of marijuana use and cancer risk. Alcohol; 2005 Apr;35(3):265-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiologic review of marijuana use and cancer risk.
  • On the other hand, marijuana smoke contains several of the same carcinogens and co-carcinogens as the tar from tobacco, raising concerns that smoking of marijuana may be a risk factor for tobacco-related cancers.
  • We reviewed two cohort studies and 14 case-control studies with assessment of the association of marijuana use and cancer risk.
  • In the cohort studies, increased risks of lung or colorectal cancer due to marijuana smoking were not observed, but increased risks of prostate and cervical cancers among non-tobacco smokers, as well as adult-onset glioma among tobacco and non-tobacco smokers, were observed.
  • The 14 case-control studies included four studies on head and neck cancers, two studies on lung cancer, two studies on non-Hodgkin's lymphoma, one study on anal cancer, one study on penile cancer, and four studies on childhood cancers with assessment of parental exposures.
  • Zhang and colleagues reported that marijuana use may increase risk of head and neck cancers in a hospital-based case-control study in the United States, with dose-response relations for both frequency and duration of use.
  • However, Rosenblatt and co-workers reported no association between oral cancer and marijuana use in a population-based case-control study.
  • An eightfold increase in risk among marijuana users was observed in a lung cancer study in Tunisia.
  • In summary, sufficient studies are not available to adequately evaluate marijuana impact on cancer risk.
  • Recommendations for future studies are to (1) focus on tobacco-related cancer sites;.
  • Despite the challenges, elucidation of the association between marijuana use and cancer risk is important in weighing the benefits and risks of medical marijuana use and to clarify the impact of marijuana use on public health.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054989.001).
  • [ISSN] 0741-8329
  • [Journal-full-title] Alcohol (Fayetteville, N.Y.)
  • [ISO-abbreviation] Alcohol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA113157; United States / NIDA NIH HHS / DA / DA/CA11386; United States / NIDA NIH HHS / DA / DA03018; United States / NCI NIH HHS / CA / T32 CA009142; United States / NCI NIH HHS / CA / CA90833; United States / NIEHS NIH HHS / ES / ES 011667; United States / NCI NIH HHS / CA / CA09142
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


30. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The radiotherapy delivered in a dose range of 55-65 Gy was used alone or in combination with chemotherapy with 5-fluoruracil, mitomycin C or Xeloda.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


31. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH: A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer; 2007 Dec 1;121(11):2465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.
  • Human papillomavirus type 16 (HPV16) plays a role in the development of a subgroup of head and neck squamous cell carcinomas (HNSCC).
  • We show that clinically meaningful viral HPV infections can be more reliably measured in FFPE HNSCC samples in a standard and high throughput manner, paving the way for prognostic and experimental vaccination studies, regarding not only HNSCC, but possibly also cancer types with HPV involvement in subgroups such as penile and anal cancer.
  • [MeSH-major] Algorithms. Carcinoma, Squamous Cell / virology. Head and Neck Neoplasms / virology. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / diagnosis. Tumor Virus Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17680565.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


32. Moscicki AB, Schiffman M, Kjaer S, Villa LL: Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine; 2006 Aug 31;24 Suppl 3:S3/42-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chapter 5: Updating the natural history of HPV and anogenital cancer.
  • The importance of the transformation zone in cervical cancer has been extended to other HPV-induced cancers such as anal or tonsillar cancers.
  • However, none are consistently associated with both except age: young women are less likely to show persistence and older women with persistence are more likely to be at risk of invasive cancer.
  • [MeSH-major] Anus Neoplasms / virology. Genital Neoplasms, Female / virology. Genital Neoplasms, Male / virology. Neoplasms / virology. Papillomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16950017.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA051323
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 45
  •  go-up   go-down


33. Shvetsov YB, Hernandez BY, Wilkens LR, Thompson PJ, Franke AA, Zhu X, Goodman MT: Plasma micronutrients and the acquisition and clearance of anal human papillomavirus infection: the Hawaii HPV cohort study. Cancer Res; 2010 Dec 1;70(23):9787-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma micronutrients and the acquisition and clearance of anal human papillomavirus infection: the Hawaii HPV cohort study.
  • Anal human papillomavirus (HPV) infection is common among women and the cause of most anal malignancies.
  • The incidence of anal cancer has been increasing among U.S. women, yet few cofactors for the natural history of anal HPV infection have been identified.
  • We examined the hypothesis that plasma carotenoid, retinol, and tocopherol concentrations are associated with the acquisition and clearance of anal HPV infection in a cohort of 279 Hawaiian residents followed at 4-month intervals for a mean duration of 16 months.
  • At each visit, interviews were conducted and biological specimens were obtained, including anal cell specimens for HPV DNA detection and genotyping, and a fasting blood sample to measure 27 micronutrients.
  • Cohort participants acquired 189 anal HPV infections, 113 of which cleared during the study period.
  • Few associations were observed between micronutrient levels and clearance of transient (≤ 150 days) anal HPV infections.
  • Our findings suggest that several carotenoids can reduce the risk and clearance of anal HPV infections that contribute to anal cancer.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Clin Microbiol. 2000 Jan;38(1):357-61 [10618116.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):876-84 [12223432.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):319-26 [12846362.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1815-20 [14600543.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Blood. 1977 Aug;50(2):327-35 [871528.001]
  • [Cites] Am J Epidemiol. 1989 Jan;129(1):125-37 [2910056.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):207-15 [7606195.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1490S-1500S [7495250.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):559-64 [8938134.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):917-23 [9367065.001]
  • [Cites] Nutr Cancer. 1998;30(1):46-52 [9507512.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):3020-7 [9738060.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):173-8 [10067816.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1861-7 [15622578.001]
  • [Cites] Parasitology. 2004 Dec;129(Pt 6):685-91 [15648691.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):629-37 [15912536.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6 [16284377.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):87-90 [16721368.001]
  • [Cites] Epidemiology. 2006 Jul;17(4):404-12 [16755268.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):672-80 [17096322.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Nutr Rev. 2007 May;65(5):181-217 [17566547.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5987-96 [17553901.001]
  • [Cites] J Infect Dis. 2008 Apr 1;197(7):957-66 [18429348.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] Nutr J. 2008;7:33 [19019244.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • [Cites] Epidemiology. 2009 Jan;20(1):36-43 [18813024.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Forum Nutr. 2009;61:75-86 [19367112.001]
  • [Cites] Carcinogenesis. 2010 Apr;31(4):533-42 [19748925.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • (PMID = 20935226.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-077318; United States / NCI NIH HHS / CA / R01 CA077318; United States / NCI NIH HHS / CA / P30-CA-71789; United States / NCI NIH HHS / CA / R01 CA077318-10; United States / NCI NIH HHS / CA / CA077318-10; United States / NCI NIH HHS / CA / P30 CA071789
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Micronutrients; 1406-66-2 / Tocopherols; 36-88-4 / Carotenoids
  • [Other-IDs] NLM/ NIHMS243669; NLM/ PMC2999639
  •  go-up   go-down


34. von Knebel Doeberitz M, Reuschenbach M: [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus]. Hautarzt; 2010 Jan;61(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus].
  • [Transliterated title] Humane Papillomviren in der Pathogenese der intraepithelialen Neoplasien (AIN) und Karzinome des Anus.
  • HPV infections have been implicated in the pathogenesis of anal cancers.
  • The mode of infection and subsequent transformation resembles very much the pathogenesis of cervical and other HPV-associated cancers.
  • The molecular dissection of individual steps required to achieve cellular transformation within an HPV-infected cell led to the identification of novel biomarkers that make it possible to identify HPV-transformed cells with substantially higher precision in comparison to conventional methods.
  • Since effective antiretroviral therapy allows for possible long-term survival of HIV-infected individuals who are at very high risk to develop HPV-associated cancers in the anogenital tract, these new developments have become increasingly relevant for practicing dermatologists and proctologists.
  • [MeSH-major] Anus Neoplasms / virology. Biomarkers, Tumor / analysis. Carcinoma in Situ / physiopathology. Papillomavirus Infections / diagnosis. Papillomavirus Infections / virology. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2007 Sep;131(9):1343-9 [17824788.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3059-63 [15131043.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3822-7 [16505361.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):307-13 [18172324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Dis Markers. 2007;23(4):297-313 [17627064.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):760-4 [17717741.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2229-42 [12441259.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] Mol Diagn Ther. 2008;12(6):395-400 [19035626.001]
  • [Cites] Lancet Oncol. 2008 Oct;9(10):937-45 [18783988.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] Arch Med Res. 2009 Aug;40(6):435-42 [19853183.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1299-307 [15520862.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Low Genit Tract Dis. 2009 Jul;13(3):145-53 [19550211.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):11-22 [17186016.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):396-403 [12845680.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):215-20 [18301250.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45 [18842994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):83-8 [18300235.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • (PMID = 20033115.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol; 2007 May 15;165(10):1143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS.
  • Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer.
  • Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry.
  • Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time.
  • Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed.
  • Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers.
  • Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32).
  • Risk of anal cancer increased after 1995 (RH = 2.9).
  • Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4).
  • The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344204.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R03-AI055270; United States / PHS HHS / / U62/CCU923549-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


36. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS: Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol; 2010 Jun;162(6):1269-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.
  • OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.
  • METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
  • Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.
  • Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.
  • Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.
  • All anal cancers carried high-risk α-HPV types.
  • All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.
  • In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).
  • In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.
  • Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.
  • CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.
  • High-grade dysplasia in these patients can progress to invasive cancer within a short period of time.
  • Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20184584.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Cinti SK, Gandhi T, Riddell J 4th: Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier? AIDS Read; 2008 Jan;18(1):18-20, 26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier?
  • Non-AIDS-defining cancers have recently gained more attention, and it appears that several of these cancers may be more common the the HAART era.
  • By most accounts in the literature, the overall risk of non-AIDS-defining cancer in HIV-infected persons is 2 to 3 times that in the general population.
  • In this article, we review the literature on 5 of the most common non-AIDS-defining cancers (Hodgkin disease, anal cancer, hepatocellular carcinoma, oral cancer, and lung cancer) in the pre- and post-HAART periods.
  • It remains unclear whether earlier initiation (CD4+ cell count above 350/microL) of antiretroviral therapy may be beneficial in preventing non-AIDS-defining cancer.
  • [MeSH-minor] Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / epidemiology. Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Humans. Liver Neoplasms / complications. Liver Neoplasms / epidemiology. Lung Neoplasms / complications. Lung Neoplasms / epidemiology. Mouth Neoplasms / complications. Mouth Neoplasms / epidemiology


38. Yako-Suketomo H, Marugame T: Comparison of time trends in colon, rectum and anus cancer incidence (1973-2002) in Asia, from 'Cancer Incidence in Five Continents, Vols IV-IX'. Jpn J Clin Oncol; 2009 Mar;39(3):196-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of time trends in colon, rectum and anus cancer incidence (1973-2002) in Asia, from 'Cancer Incidence in Five Continents, Vols IV-IX'.
  • [MeSH-major] Anus Neoplasms / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233893.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos Gimenez F, Gonçalves Guimarães RA, Botinelly Fujimoto L, Barbosa Cabral CR, Venturim Mozzer R, de Souza Atala L: High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann Surg Oncol; 2008 May;15(5):1470-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients.
  • BACKGROUND: Renal graft recipients are one of the population groups known to be at high risk of developing anal cancer.
  • This study investigated the presence of subclinical anal squamous intraepithelial lesions and the diagnostic ability of high-resolution anoscopy in detecting these lesions in renal graft recipients followed-up in Manaus.
  • METHODS: In a cross-sectional study, 50 renal graft recipients were interviewed and submitted to high-resolution anoscopy with biopsies of acetowhite lesions or of the anal transition zone mucosa when acetowhitening was absent.
  • Considering the histopathological reports of the examined anal specimens as the gold standard, the diagnostic validation and precision measures of high-resolution anoscopy were calculated as well as the prevalence of anal squamous intraepithelial lesions in the studied population.
  • RESULTS: In 42 renal graft recipients with satisfactory histopathological readings, prevalence of anal squamous intraepithelial lesions or condyloma acuminatum (ASIL-ACU) was 23.81%.
  • CONCLUSIONS: With a prevalence of 23.81% of subclinical ASIL-ACU lesions, the studied renal graft recipients had all these lesions detected by high-resolution anoscopy, notwithstanding most anal transition zone acetowhitened biopsied areas did not reveal histopathological aspects of anal cancer precursor lesions or condyloma acuminatum.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Kidney Transplantation


40. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of the sentinel node biopsy in anal cancer.
  • AIM: Anal cancer is a rare neoplasm.
  • According to a European Organization for Research and Treatment of Cancer multivariate analysis, synchronous inguinal lymph node metastasis occurs in 10-25% of patients and constitutes an independent prognostic factor for local failure and overall mortality.
  • METHODS: Inguinal lymph node status was assessed using the sentinel node technique in 35 patients with anal cancer.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol; 2010;5:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
  • PURPOSE: To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course chemoradiation (CRT).
  • METHODS: From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT.
  • Significant anal pain or fecal incontinence was infrequently reported.
  • CONCLUSIONS: Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and long-term global QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Quality of Life. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):282-5 [3986477.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):107-13 [17707936.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):239-43 [10580870.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(2):189-93 [17189954.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1564-73 [17521904.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 20492729.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2883545
  •  go-up   go-down


43. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S: Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer; 2010 Dec 07;103(12):1858-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.
  • BACKGROUND: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC).
  • This systematic review examines current prognostic markers in SCC of the anus.
  • METHODS: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
  • CONCLUSIONS: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer.
  • [MeSH-major] Anus Neoplasms / mortality. Biomarkers, Tumor. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Angiogenesis. 2008;11(4):321-35 [18925424.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):45-55 [18506774.001]
  • [Cites] Pathol Oncol Res. 2008 Dec;14(4):345-54 [18493868.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(1):31-9 [19221643.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 May;37(5):544-56 [19233691.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1792(4):229-39 [19419697.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3725-32 [19458054.001]
  • [Cites] Curr Drug Targets. 2009 Jul;10(7):581-9 [19601762.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Adv Genet. 2009;67:1-27 [19914448.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6213-21 [19884544.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):361-8 [20010949.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Cancer Biol Ther. 2010 Jan;9(1):23-30 [19923884.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):618-35 [15234243.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1239-44 [15292923.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):782-5 [3367186.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1745-55 [20215558.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Dig Dis Sci. 2010 Apr;55(4):1098-105 [19399614.001]
  • [Cites] Head Neck Oncol. 2010;2:8 [20398256.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):24-35 [20530316.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Clin Chem. 2000 Mar;46(3):313-8 [10702516.001]
  • [Cites] J Surg Oncol. 2000 Jun;74(2):163-6 [10914829.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9 [11098307.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1768-72 [11100055.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Dec;19(4):471-5 [11277325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1355-8 [11677963.001]
  • [Cites] Nat Rev Neurosci. 2002 Jan;3(1):24-33 [11823802.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):1-14 [11880176.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] Med Oncol. 2003;20(3):221-31 [14514971.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6489-96 [14695153.001]
  • [Cites] Dis Colon Rectum. 1991 Feb;34(2):126-31 [1993409.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1251-7 [1650445.001]
  • [Cites] EMBO J. 1992 Mar;11(3):961-71 [1312467.001]
  • [Cites] Acta Oncol. 1992;31(3):333-5 [1622654.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):98-102 [7691975.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):697-709 [7881344.001]
  • [Cites] Cancer Metastasis Rev. 1995 Mar;14(1):3-15 [7606818.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1096-100 [7576999.001]
  • [Cites] Virchows Arch. 1996 May;428(2):85-9 [8925129.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):369-73 [8784470.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int Surg. 1997 Jul-Sep;82(3):275-9 [9372374.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1831-5 [9815570.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Acta Histochem. 2005;107(2):87-93 [15950051.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] BMC Med Res Methodol. 2007;7:10 [17302989.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):376-86 [18223558.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1264-73 [18349847.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):946-53 [18396036.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • (PMID = 21063399.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC3008609
  •  go-up   go-down


44. Human papillomavirus: often harmless but in some cases carcinogenic. Prescrire Int; 2007 Jun;16(89):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 100 genotypes of human papillomavirus (HPV) have been identified; they differ in targeted tissue and carcinogenic activity. (2) This article describes the clinical manifestations, prevalence and modes of transmission of human papillomavirus infections, and the role of HPV in human cancer.
  • Various factors, especially immunosuppression, increase the persistence and severity of infections, and can promote progression to cancer. (7) The DNA of some highly carcinogenic HPV genotypes (especially HPV-16 and HPV-18) is present in 95% to 100% of cervical epidermoid tumours.
  • Malignant transformation of lesions due to HPV seems to be facilitated by HPV persistence, a high HPV viral load in the cervix, and immunosuppression. (8) However, HPV infection rarely leads to progression to cancer.
  • About 5% of high-grade lesions progress to invasive cancer. (9) Other anogenital cancers, such as cancer of the anus, vulva, vagina and penis, appear to be linked to HPV (usually genotype 16). (10) Skin cancer due to HPV is rare.
  • Some cancers of the respiratory and gastrointestinal tracts appear to be linked to HPV infection.
  • [MeSH-minor] Anus Neoplasms / genetics. Anus Neoplasms / virology. DNA, Viral. Female. Humans. Immunosuppression. Male. Papillomaviridae / metabolism. Sexually Transmitted Diseases, Viral. Skin Neoplasms / genetics. Skin Neoplasms / virology. Urogenital Neoplasms / genetics. Urogenital Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585425.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


45. Chapet O, Gerard JP, Mornex F, Goncalves-Tavan S, Ardiet JM, D'hombres A, Favrel V, Romestaing P: Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience. Int J Colorectal Dis; 2007 Feb;22(2):191-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience.
  • BACKGROUND: To report our patient experience with squamous cell carcinoma of the anal margin and to evaluate the prognostic factors influencing outcome.
  • MATERIALS AND METHODS: Between 1980 and 2001, 26 patients with anal margin squamous cell carcinoma were treated in Lyon-Sud: 7 T1, 14 T2, 4 T3, and 1 T4 with 20 N0, 3 N1, and 3 N2.
  • The anal canal was invaded in five patients.
  • Three factors correlated with specific survival: cell differentiation (P=0.038) and T (P=0.001) and N category (P=0.0005).
  • CONCLUSION: Our results confirm the dominating place of definitive irradiation and radiochemotherapy in the treatment of anal margin squamous cell carcinoma.
  • The prognosis of squamous cell carcinoma is correlated to T and N staging and cell differentiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasms, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] Proc R Soc Med. 1968 Jun;61(6):629-30 [4173822.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1843-8; discussion 1848, 1853-4 [8985968.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):231-4 [371426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):57-66 [9300740.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Radiother Oncol. 1995 Mar;34(3):195-202 [7631025.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):799-808 [2202568.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Surg Gynecol Obstet. 1979 Apr;148(4):576-8 [432774.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Acta Oncol. 2001;40(1):29-33 [11321656.001]
  • [Cites] Radiother Oncol. 1988 Jan;11(1):1-6 [3344351.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 16799791.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Lorence RM: A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res; 2006 Apr 15;12(8):2555-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor regression was observed in a patient with anal carcinoma who enrolled with stable disease following palliative radiotherapy.
  • Four patients with clearly progressing cancer before enrollment had disease stabilization of >/=6 months.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638865.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. van Lieshout A, Pronk A: [Increasing incidence of anal cancer in the Netherlands]. Ned Tijdschr Geneeskd; 2010;154:A1163
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing incidence of anal cancer in the Netherlands].
  • Anal cancer is a rare malignancy with a rapidly rising incidence.
  • The most important risk factor for anal cancer is persistent infection with Human papillomavirus (HPV).
  • In the Netherlands, the incidence of anal cancer increased from 71 to 149 new patients each year over the period 1989-2006.
  • Not enough research has been done to date to clarify why the incidence of anal cancer is increasing.
  • [MeSH-major] Anus Neoplasms / epidemiology. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456793.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 11
  •  go-up   go-down


48. Das P, Crane CH, Eng C, Ajani JA: Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res; 2008 Jan;2(1):10-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for squamous cell cancer of the anal canal.
  • Radiotherapy with concurrent chemotherapy is the standard of care for patients with nonmetastatic squamous cell anal cancer.
  • However, some heterogeneity exists among anal cancer patients in their outcomes.
  • This article reviews some of the clinical factors, treatment-related factors, and biologic factors that affect outcomes in patients with squamous cell anal cancer.
  • A better understanding of molecular biology is required to characterize the inherent heterogeneity of anal cancer and thereby develop optimal therapies.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):893-8 [15821121.001]
  • [Cites] Radiat Oncol. 2006;1:29 [16916475.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1047-53 [16865595.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1316-24 [16169674.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1347-55 [15719440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):67-73 [7690019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):53-8 [2492441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):56-8 [2803916.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1986 May;29(5):336-40 [3698757.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):159-64 [3969957.001]
  • [Cites] Histopathology. 1990 Jun;16(6):545-55 [2376397.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):411-5 [7237411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):229-33 [10782881.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19259318.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2630809
  •  go-up   go-down


49. Oehler C, Provencher S, Donath D, Bahary JP, Lütolf UM, Ciernik IF: Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. Radiat Oncol; 2010;5:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.
  • BACKGROUND: The split-course schedule of chemo-radiation for anal cancer is controversial.
  • METHODS: Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed.
  • Patients from Zurich with prolonged treatment interruption (> or = 7 d) had impaired cancer-specific survival compared with patients with only minor interruption (<7 d) (P = 0.06).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Onkologie. 2008 May;31(5):251-7 [18497514.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):367-75 [18501453.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):91-6 [11033193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • (PMID = 20465811.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2879246
  •  go-up   go-down


50. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


51. Glynne-Jones R, Mawdsley S: Anal cancer: the end of the road for neoadjuvant chemoradiotherapy? J Clin Oncol; 2008 Aug 1;26(22):3669-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Jan 1;27(1):162-3; author reply 163 [19047300.001]
  • [CommentOn] J Clin Oncol. 2007 Nov 20;25(33):5281-6 [18024876.001]
  • (PMID = 18519948.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC: Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr; 2009 Oct 1;52(2):203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For HIV-infected patients, CD4 counts closest to first observation date were compared between those with and without cancer.
  • Incidence rate ratio for individual cancers was highest for anal cancer (14.9; confidence interval: 10.1 to 22.1).
  • Among HIV-infected patients, median CD4 counts were lower for those with non-ADM (249 vs. 270, P = 0.02), anal cancer (156 vs. 270; P < 0.001), and Hodgkin lymphoma (217 vs. 269; P = 0.03).
  • Prostate cancer was associated with a higher CD4 count (311 vs. 266; P < 0.001).


53. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer; 2010;10:189
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
  • BACKGROUND: With the availability of effective anti-EGFR therapies for various solid malignancies, such as non-cell small lung cancer, colorectal cancer and squamous cell carcinoma of the head and neck, the knowledge of EGFR and K-RAS status becomes clinically important.
  • The aim of this study was to analyse EGFR expression, EGFR gene copy number and EGFR and K-RAS mutations in two cohorts of squamous cell carcinomas, specifically anal canal and tonsil carcinomas.
  • METHODS: Formalin fixed, paraffin-embedded tissues from anal and tonsil carcinoma were used.
  • For the K-RAS gene, PCR was performed using exon 2 specific primers.
  • RESULTS: EGFR immunoreactivity was present in 36/43 (83.7%) of anal canal and in 20/24 (83.3%) of tonsil squamous cell carcinomas.
  • EGFR amplification was absent in anal canal tumours (0/23), but could be identified in 4 of 24 tonsil tumours.From 38 anal canal specimens, 26 specimens were successfully analysed for exon 18, 30 for exon 19, 34 for exon 20 and 30 for exon 21.
  • CONCLUSION: EGFR mutations were absent from squamous cell carcinoma of the anus and tonsils, but EGFR protein expression was detected in the majority of the cases.
  • EGFR amplification was seen in tonsil but not in anal canal carcinomas.
  • In our investigated panel, only one mutation in the K-RAS gene of a tonsil squamous cell carcinoma was identified.
  • This indicates that EGFR and K-RAS mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in anal canal and tonsil squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Tonsillar Neoplasms / genetics. ras Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / chemistry. Anal Canal / pathology. Base Sequence. Belgium. Cohort Studies. DNA Mutational Analysis. Exons. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Molecular Sequence Data. Mutation. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2000 Jan;36(1):76-80 [10889924.001]
  • [Cites] Oncology. 2009;77(5):293-9 [19923868.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):893-901 [15208356.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1037-43 [2197591.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] Laryngoscope. 1994 Nov;104(11 Pt 1):1337-47 [7968162.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):109-11 [16324836.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):520-6 [17224267.001]
  • [Cites] Oncologist. 2007 Jan;12(1):90-8 [17285735.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2164-70 [17538160.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] Tumour Biol. 2007;28(5):273-9 [17962724.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):508-15 [17998284.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1180-7 [18422739.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] Head Neck. 2008 Aug;30(8):1040-4 [18528899.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1589-94 [18754871.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):289-97 [18768215.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):857-66 [11231940.001]
  • (PMID = 20459770.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2887399
  •  go-up   go-down


54. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology


55. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M, FHDH-ANRS CO 4: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS; 2008 Jun 19;22(10):1203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.
  • OBJECTIVE: To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer.
  • METHODS: We examined the incidence rates of anal cancer between 1992 and 2004 and the risk associated among 86,322 HIV-infected patients included in the French Hospital Database on HIV.
  • RESULTS: We identified 132 cases of anal cancer, including 124 cases in men (94%), of whom 75% had sex with men.
  • Median age at diagnosis was 42.8 years (interquartile range: 36.9-49.4).
  • At diagnosis, 103 patients (78%) were receiving combination antiretroviral therapy for a median of 37.1 months (interquartile range: 4.5-59.8).
  • Median survival after anal cancer diagnosis was 5 years.
  • The respective overall incidence rates of anal cancer per 100,000 person-years between 1992 and March 1996, April 1996 to 1998 and between 1999 and 2004 were 11 (95% confidence interval, 4-17), 18 (95% confidence interval, 10-27) and 40 (95% confidence interval, 32-47).
  • The risk of anal cancer was higher among men who have sex with men.
  • After adjustment for age at inclusion in the study, as well as gender, the HIV transmission group, the nadir CD4 cell count and AIDS status, the incidence was higher in the years 1999-2004 than in between 1992 to March 1996 (hazard ratio, 2.5; 95% confidence interval, 1.2-5.3), with no change in the years 1999-2004.
  • CONCLUSION: The incidence of anal cancer has increased among HIV-infected patients in France since 1996.
  • Although an ascertainment bias cannot be excluded, data indicate that combination antiretroviral therapy does not prevent anal cancer in these patients.
  • This supports the urgent need for developing anal cancer screening programs for HIV-infected men who have sex with men.
  • [MeSH-major] Anus Neoplasms / mortality. HIV Infections / mortality. Homosexuality, Male / statistics & numerical data

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525266.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Costagliola D; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Aronica E; Pariente-Khayat A; Jacquemet N; Rivet A; Abgrall S; Costagliola D; Grabar S; Guiguet M; Lanoy E; Selinger-Leneman H; Liévre L; Mary-Krause M; Potard V; Bouvet E; Crickx B; Ecobichon JL; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Gilquin J; Roudiére L; Viard JP; Boué F; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit PH; Desplanque N; Meynard JL; Meyohas MC; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont JP; Moreau J; Gastaut JA; Poizot-Martin I; Retornaz F; Soubeyrand J; Allegre T; Blanc TA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Pradier C; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang JM; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Gustave Dron CF; Yasdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M
  •  go-up   go-down


56. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R: Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology; 2005 May-Jun;52(63):780-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
  • We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.
  • Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.
  • The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.
  • Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.
  • It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966204.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


57. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Truesdale MD, Goldstone SE: The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men. Int J STD AIDS; 2010 Jul;21(7):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men.
  • Human papillomavirus (HPV)-related anal cancer incidence is rising in men who have sex with men (MSM).
  • Retrospective chart review identified MSM with anal dysplasia.
  • Questionnaires were completed after anal dysplasia diagnosis.
  • RF were more likely to describe their HPV diagnosis as 'upsetting' (P = 0.003).
  • Positive predictors for screening compliance include an upsetting experience during the HPV diagnosis, physical symptoms driving the initial visit and HSIL.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / psychology. Early Detection of Cancer / psychology. Homosexuality, Male. Papillomavirus Infections / diagnosis. Patient Compliance / statistics & numerical data


59. Raghunathan G, Mortele KJ: Magnetic resonance imaging of anorectal neoplasms. Clin Gastroenterol Hepatol; 2009 Apr;7(4):379-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among imaging techniques, magnetic resonance imaging (MRI) has evolved as the most robust technique for the detection, characterization, and staging of anorectal cancers.
  • In this article we aim to outline the various types of anorectal cancers, highlight the complex anatomy of this region, and discuss the immensely useful role of MRI in the management of anorectal cancers.
  • This will be followed by an overview of MRI in anal carcinoma and other less common anorectal neoplasms.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340959.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


60. Stieler F, Wolff D, Lohr F, Steil V, Abo-Madyan Y, Lorenz F, Wenz F, Mai S: A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT). Radiat Oncol; 2009;4:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT).
  • BACKGROUND/PURPOSE: Radiotherapy (RT) volumes for anal cancer are large and of moderate complexity when organs at risk (OAR) such as testis, small bowel and bladder are at least partially to be shielded.
  • MATERIALS AND METHODS: Based on treatment planning CTs of 8 patients, we compared dose distributions, comformality index (CI), homogeneity index (HI), number of monitor units (MU) and treatment time (TTT) for plans generated for VMAT, 3D-CRT and step-and-shoot-IMRT (optimized based on Pencil Beam (PB) or Monte Carlo (MC) dose calculation) for typical anal cancer planning target volumes (PTV) including inguinal lymph nodes as usually treated during the first phase (0-36 Gy) of a shrinking field regimen.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Radiotherapy / methods. Radiotherapy Planning, Computer-Assisted


61. Mai SK, Welzel G, Hermann B, Wenz F, Haberkorn U, Dinter DJ: Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol; 2009 Apr;185(4):254-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced?
  • PURPOSE: To investigate whether a dose reduction to CT-enlarged but FDG-PET-negative (([(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography) inguinal lymph nodes in radiochemotherapy of anal cancer is safe.
  • PATIENTS AND METHODS: 39 sequential patients with anal cancer (mean age 59 years [range: 37-86 years], median follow-up 26 months [range: 3-51 months]) receiving pretherapeutic FDG-PET were included.
  • CONCLUSION: Reduction of the irradiation dose to CT-enlarged but PET-negative inguinal lymph nodes in anal cancer seems not to result in increased failure rates.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / radiotherapy. Body Burden. Fluorodeoxyglucose F18. Lymph Nodes / radiation effects. Positron-Emission Tomography / methods. Radiation Protection / methods. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):100-4 [18259702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:21-3 [18167002.001]
  • [Cites] Rev Med Interne. 1993 May;14(5):340-9 [8235150.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:41-2 [18167009.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):804-8 [12029555.001]
  • [Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):483-99 [16044216.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Onkologie. 2002 Feb;25(1):55-9 [11893884.001]
  • [Cites] Onkologie. 2008 May;31(5):251-7 [18497514.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):369-75 [16826354.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Strahlenther Onkol. 1998 Feb;174(2):108-9 [9487375.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Strahlenther Onkol. 2008 Apr;184(4):206-11 [18398585.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 19370429.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Echenique I, Cabanillas F, Texidor V, Cáceres J, Isenberg G, Claudio C, Ayala R, Madera F: A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management. Bol Asoc Med P R; 2009 Apr-Jun;101(2):53-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management.
  • All sphincter saving rectal cancer operations results for ultra-low tumors need to be as good as results from an APR.
  • Performing frozen section for the ultralow rectal cancer margins is recommended.
  • Color Doppler evaluation has shown higher specificity than that of grey scale ultrasound in staging and differentiating scar from anal cancers.
  • CONCLUSION: At this point with the information available from the literature, we suggest that patients with clinically advanced rectal cancer can have a distal margin resection of less than 2 cm if: 1- the tumor is not mucin producing, 2- the tumor is not high-grade, and 3- the response to preop CRX is adequate, however there exist no clear guidelines available to judge what is an excellent versus a moderate or poor response.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Practice Guidelines as Topic. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954103.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


63. Graziottin A, Serafini A: HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions. J Sex Med; 2009 Mar;6(3):633-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV is a wide family of DNA viruses, which may cause benign skin and mucosal tumors (genital, anal, or oral warts), intraepithelial neoplasias, and/or malignant cancers in different organs.
  • (ii) HPV-related genital, oral, and anal precancerous lesions on women's sexual function.
  • Search terms were HPV, GWs, intraepithelial neoplasia, cervical cancer, anal cancer, oral cancer, epidemiology, HPV risk factors, sexual dysfunctions, desire disorders, arousal disorders, dyspareunia, vulvar vestibulitis, vulvodynia, orgasmic difficulties, sexual repertoire, couple sexual problems, depression, anxiety, pap smear, screening program, therapy, and vaccines.
  • However, to date, there is no conclusive evidence of a specific correlation between HPV infection and a specific female sexual disorder.
  • [MeSH-major] Condylomata Acuminata / psychology. Epithelium / pathology. Epithelium / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Papillomavirus Infections / epidemiology. Sexual Dysfunctions, Psychological / diagnosis. Sexual Dysfunctions, Psychological / epidemiology
  • [MeSH-minor] Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Depressive Disorder / epidemiology. Depressive Disorder / psychology. Dyspareunia / epidemiology. Female. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19170869.001).
  • [ISSN] 1743-6109
  • [Journal-full-title] The journal of sexual medicine
  • [ISO-abbreviation] J Sex Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


64. Brewer NT, Ng TW, McRee AL, Reiter PL: Men's beliefs about HPV-related disease. J Behav Med; 2010 Aug;33(4):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While human papillomavirus (HPV) infection is associated with genital warts, anal cancer, and oral cancer, limited research has examined what men think causes these diseases.
  • We sought to examine knowledge and beliefs about HPV-related disease among gay and bisexual men, who are at high risk for HPV infection and HPV-related cancers, and compare them to heterosexual men.
  • Fewer than half of men knew that HPV can cause genital warts (41%), anal cancer (24%), and oral cancers (23%).
  • Overall, most men believed that sexual behavior causes genital warts (70%) and anal cancer (54%), and tobacco use causes oral cancer (89%).
  • Many men were unaware that HPV infection can cause genital warts, oral cancer, and anal cancer.

  • MedlinePlus Health Information. consumer health - Sexual Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):3036-46 [18980286.001]
  • [Cites] Int J STD AIDS. 2009 Apr;20(4):290-1 [19304982.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Prev Med. 2009 May;48(5):411-4 [18996144.001]
  • [Cites] Am J Public Health. 2010 Jun;100(6):1123-9 [20395576.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Nicotine Tob Res. 2003 Dec;5(6):821-6 [14668066.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Clin Microbiol. 1995 Aug;33(8):2058-63 [7559948.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):845-51 [15805354.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] J Med Screen. 2006;13(4):201-7 [17217610.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):130-4 [17707077.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] J Womens Health (Larchmt). 2008 May;17(4):539-48 [18370586.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] Nicotine Tob Res. 2008 Oct;10(10):1559-70 [18946775.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):363-72 [19190161.001]
  • (PMID = 20162346.001).
  • [ISSN] 1573-3521
  • [Journal-full-title] Journal of behavioral medicine
  • [ISO-abbreviation] J Behav Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS578640; NLM/ PMC4018629
  •  go-up   go-down


65. Parés D, Mullerat J, Pera M: [Anal intraepithelial neoplasia]. Med Clin (Barc); 2006 Nov 18;127(19):749-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia].
  • [Transliterated title] Neoplasia intraepitelial anal.
  • Human papillomavirus (HPV) is responsible for anal condylomata, anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma.
  • AIN is a premalignant condition that can progress to invasive carcinoma through different grades of severity of the disease called AIN I, AIN II and AIN III.
  • The groups at risk are mainly patients with infection with human immunodeficiency virus, immunossuppressed patients and patients affected by HPV related diseases (e.g., cervical cancer or anal condyloma).
  • Accurate diagnosis of AIN lesions consists of accurate grading and disease extension.
  • Low grade AIN (AIN I) or in extensive lesions, follow-up is advised to determine the possible evolution to anal squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Humans

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198654.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 58
  •  go-up   go-down


66. Poizot-Martin I, Henry M, Benhaim S, Obry-Roguet V, Figarella D, Tamalet C: High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients. J Clin Virol; 2009 Apr;44(4):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.
  • BACKGROUND: Despite HAART, the prevalence and incidence of anal cancer in HIV-infected individuals have increased.
  • Recently, the relationship between the severity of cervical lesions and oncogenic HPV load was demonstrated; however, few studies have assessed the level and the significance of oncogenic HPV load in patients at risk for anal neoplasia.
  • OBJECTIVES: To assess HPV genotypes and HPV 16/18 DNA load in HIV-1 infected patients at risk for anal neoplasia.
  • STUDY DESIGN: Cross-sectional pilot study from male and female HIV-1 infected individuals at risk for anal neoplasia in an outpatient HIV Clinical Unit of Marseilles university Hospitals.
  • RESULTS: Anal HPV was found in 79% of the patients whereas high-risk (HR) HPV types and infection with multiple HPV types were found in 83% and 61% of the patients, respectively.
  • CONCLUSIONS: Longitudinal studies are needed to evaluate the link between high anal HPV DNA load and progression to anal squamous intraepithelial lesions and anal cancer.
  • [MeSH-major] Anal Canal / virology. DNA, Viral / isolation & purification. HIV Infections / complications. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269245.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


67. Gurfinkel R, Walfisch S: Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis. Tech Coloproctol; 2005 Dec;9(3):235-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis.
  • The combination of chemotherapy and radiotherapy with subsequent repeated local biopsy has become the standard treatment of epidermoid carcinoma.
  • The optimal treatment of metastatic anal carcinomas is controversial.
  • We present the case of 54-year-old woman with a diagnosis of metastatic basaloid anal carcinoma.
  • The patient underwent resection of liver metastasis in combination with cisplatin + 5FU and local radiotherapy, without evident disease 3 years after diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328122.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Sana S, Khan AU: Clinical trials in the management of anal cancer. Clin Colon Rectal Surg; 2009 May;22(2):115-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials in the management of anal cancer.
  • Our understandings of anal canal cancer pathogenesis and treatment have undergone significant changes due to continuing research into its pathogenesis and the results of major clinical trials conducted over the past 20 years.
  • Anal canal cancer can be cured by combined modality chemoradiation therapy, a treatment that preserves continence and reserves abdominoperineal resection of the rectum and anal canal in patients with recurrent or residual disease after primary chemoradiotherapy.
  • Future challenges include an increasing incidence of human papillomavirus infection, the AIDS epidemic, diagnosis of early disease, and optimization of chemotherapy and radiation regimens.
  • This article aims to provide a summary of recently completed and ongoing clinical trials in the management of anal canal cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26 [18472366.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • (PMID = 20436836.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780239
  • [Keywords] NOTNLM ; Anal canal cancer / chemotherapy / radiation therapy
  •  go-up   go-down


69. Kim T, Chae G, Chung SS, Sands DR, Speranza JR, Weiss EG, Nogueras JJ, Wexner SD: Faecal incontinence in male patients. Colorectal Dis; 2008 Feb;10(2):124-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common prior diagnosis in group A was perianal sepsis in 23 (11.3%) patients and symptomatic haemorrhoids in 20 (9.9%) patients; in group B it was prostate cancer in 57 (28.4%) patients, symptomatic haemorrhoids in 31 (15.4%) patients and neurological diseases in 18 (9%) patients.
  • In group B, radiation therapy for prostate cancer was utilized in 48 (23.9%) patients and haemorrhoidectomy in 29 (14.4%) patients.
  • Comparing group A and group B relative to diagnosis - perianal sepsis, perineal trauma, congenital disorders, HIV infection and anal cancer were more common in group A, whereas prostate cancer, neurological diseases and colon cancer were significantly more common in group B.
  • CONCLUSION: Prostate cancer, symptomatic haemorrhoids, perianal sepsis, rectal cancer and a history of restorative rectal resection were common associations with FI in men.

  • Genetic Alliance. consumer health - Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498204.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Lin K, Doolan K, Hung CF, Wu TC: Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc; 2010 Jan;109(1):4-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human Papillomavirus (HPV) has been associated with several human cancers, including cervical cancer, vulvar cancer, vaginal and anal cancer, and a subset of head and neck cancers.
  • However, these are unlikely to impact upon HPV prevalence and cervical cancer rates for many years.
  • These vaccines aim to generate a cell-mediated immune response to infected cells.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / administration & dosage. Uterine Cervical Neoplasms / prevention & control. Vaccination / trends. Viral Vaccines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharm. 2008 May-Jun;5(3):464-71 [18266319.001]
  • [Cites] Vaccine. 2008 Jun 19;26(26):3362-70 [18471945.001]
  • [Cites] Gene Ther. 2008 Jul;15(13):1007-16 [18356819.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):93-101 [18575754.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):725-30 [10797297.001]
  • [Cites] Gene Ther. 2000 May;7(9):726-33 [10822298.001]
  • [Cites] Mol Cell. 2000 Mar;5(3):557-67 [10882140.001]
  • [Cites] Clin Exp Immunol. 2000 Aug;121(2):216-25 [10931134.001]
  • [Cites] J Virol. 2000 Sep;74(18):8700-8 [10954571.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5456-63 [11034088.001]
  • [Cites] Hum Gene Ther. 2001 Feb 10;12(3):235-52 [11177561.001]
  • [Cites] J Virol. 2001 Mar;75(5):2368-76 [11160740.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1080-8 [11221836.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5733-40 [11313416.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3698-703 [11325841.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):669-78 [11544272.001]
  • [Cites] J Virol. 2001 Oct;75(20):9654-64 [11559797.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7861-7 [11691804.001]
  • [Cites] Adv Exp Med Biol. 2001;495:419-27 [11774604.001]
  • [Cites] Appl Environ Microbiol. 2002 Feb;68(2):917-22 [11823236.001]
  • [Cites] Hum Gene Ther. 2002 Mar 1;13(4):553-68 [11874633.001]
  • [Cites] J Virol. 2004 Feb;78(3):1333-43 [14722288.001]
  • [Cites] Trends Mol Med. 2004 Jan;10(1):15-8 [14720581.001]
  • [Cites] Gene Ther. 2004 Feb;11(3):336-42 [14737094.001]
  • [Cites] Obstet Gynecol. 2004 Feb;103(2):317-26 [14754702.001]
  • [Cites] Virology. 2004 Feb 20;319(2):237-48 [14980484.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):241-51 [15050916.001]
  • [Cites] J Med Microbiol. 2004 May;53(Pt 5):427-33 [15096553.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2954-61 [15131030.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1581-8 [15138603.001]
  • [Cites] Gene Ther. 2004 Jun;11(12):1011-8 [14985791.001]
  • [Cites] Cancer Gene Ther. 2004 Jun;11(6):457-64 [15118761.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):278-85 [15197783.001]
  • [Cites] Vaccine. 2004 Jul 29;22(21-22):2722-9 [15246603.001]
  • [Cites] J Virol. 2004 Aug;78(16):8468-76 [15280455.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):971-82 [15297964.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1487-95 [9390747.001]
  • [Cites] Virology. 1997 Dec 22;239(2):389-401 [9434729.001]
  • [Cites] J Virol. 1998 Feb;72(2):950-8 [9444987.001]
  • [Cites] J Virol. 1998 Jul;72(7):6151-4 [9621080.001]
  • [Cites] J Biomed Sci. 1998 Jul-Aug;5(4):231-52 [9691216.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):593-7 [10024696.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1184-7 [10096544.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):428-37 [10209958.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] Vaccine. 2004 Dec 16;23(5):629-38 [15542183.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8821-5 [15604239.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):311-7 [15643517.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):309-16 [15665308.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):641-9 [15695409.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2476-80 [15728450.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Drug Target. 2005 Feb;13(2):89-98 [15823960.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):559-67 [15863160.001]
  • [Cites] Vaccine. 2005 May 25;23(28):3634-41 [15882523.001]
  • [Cites] Hum Gene Ther. 2005 May;16(5):584-93 [15916483.001]
  • [Cites] Gene Ther. 2005 Aug;12(15):1180-6 [15800656.001]
  • [Cites] Gene Ther. 2005 Sep;12(18):1410-4 [15843807.001]
  • [Cites] Immunology. 2005 Oct;116(2):255-66 [16162274.001]
  • [Cites] J Virol. 2005 Oct;79(20):12807-17 [16188983.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):9089-98 [16204084.001]
  • [Cites] Cancer Immunol Immunother. 2005 Dec;54(12):1180-90 [15846491.001]
  • [Cites] Vaccine. 2005 Nov 1;23(45):5271-80 [16054734.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2727-40 [10584920.001]
  • [Cites] Vet Immunol Immunopathol. 1999 Dec 15;72(1-2):189-202 [10614509.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]
  • [Cites] Vaccine. 2000 Apr 3;18(19):2015-22 [10706963.001]
  • [Cites] Vaccine. 2004 Sep 9;22(27-28):3738-43 [15315854.001]
  • [Cites] Vaccine. 2004 Sep 28;22(29-30):3993-4001 [15364449.001]
  • [Cites] Virology. 1991 Nov;185(1):251-7 [1656586.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4 [1334560.001]
  • [Cites] J Gen Virol. 1994 Aug;75 ( Pt 8):2075-9 [8046412.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] Lancet. 1996 Jun 1;347(9014):1523-7 [8684105.001]
  • [Cites] Trends Biochem Sci. 1996 Apr;21(4):122-6 [8701466.001]
  • [Cites] J Virol. 1997 Apr;71(4):2988-95 [9060658.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):630-7 [9178819.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):178-87 [18172269.001]
  • [Cites] Vaccine. 2008 Mar 4;26(10):1387-96 [18272260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5 [18413606.001]
  • [Cites] Hum Gene Ther. 2008 Apr;19(4):354-64 [18439124.001]
  • [Cites] J Immunol. 2008 May 15;180(10):7019-27 [18453624.001]
  • [Cites] J Transl Med. 2008;6:21 [18445282.001]
  • [Cites] Curr Pharm Des. 2005;11(27):3485-500 [16248803.001]
  • [Cites] Obstet Gynecol. 2006 Jan;107(1):18-27 [16394035.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):469-78 [16249018.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5527-36 [16740684.001]
  • [Cites] Vaccine. 2006 Jun 12;24(24):5235-44 [16675074.001]
  • [Cites] Vaccine. 2006 Jul 7;24(27-28):5571-83 [16753240.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1075-81 [16803488.001]
  • [Cites] J Biomed Sci. 2006 Jul;13(4):481-8 [16649071.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):2135-45 [17079588.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):41-51 [17186030.001]
  • [Cites] Cancer Immun. 2007;7:2 [17279610.001]
  • [Cites] Expert Rev Vaccines. 2007 Apr;6(2):227-39 [17408372.001]
  • [Cites] Vaccine. 2007 Apr 30;25(17):3302-10 [17291642.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jul;56(7):997-1007 [17146630.001]
  • [Cites] Pediatr Infect Dis J. 2007 Mar;26(3):201-9 [17484215.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1211-9 [17356542.001]
  • [Cites] Blood. 2007 Jul 1;110(1):186-92 [17392506.001]
  • [Cites] Curr Mol Med. 2007 Jun;7(4):339-50 [17584074.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] Curr Mol Med. 2007 Aug;7(5):490-503 [17691964.001]
  • [Cites] Adv Exp Med Biol. 2007;601:345-55 [17713023.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):453-60 [17586030.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):169-77 [18172268.001]
  • [Cites] Hum Gene Ther. 2008 Aug;19(8):763-73 [18627219.001]
  • [Cites] Vaccine. 2008 Sep 26;26(41):5315-20 [18680778.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):361-7 [19118066.001]
  • [Cites] Vaccine. 2009 Jan 29;27(5):701-7 [19041356.001]
  • [Cites] Vaccine. 2009 Jan 29;27(5):684-9 [19056449.001]
  • [Cites] Immunol Lett. 2009 Jan 29;122(1):58-67 [19135479.001]
  • [Cites] Cancer Immunol Immunother. 2009 May;58(5):737-48 [18815785.001]
  • [Cites] J Biomed Sci. 2009;16:36 [19338665.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):189-98 [19358269.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4319-26 [19435920.001]
  • [Cites] Lancet Infect Dis. 2009 Jun;9(6):347-56 [19467474.001]
  • [Cites] Vaccine. 2009 Jun 19;27(30):3975-83 [19389451.001]
  • [Cites] Vaccine. 2009 Jul 9;27(32):4363-9 [19481843.001]
  • [Cites] J Biomed Sci. 2009;16:49 [19473507.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1365-72 [19471247.001]
  • [Cites] Vaccine. 2009 Sep 4;27(40):5450-9 [19622402.001]
  • [Cites] Vaccine. 2009 Sep 18;27(41):5612-9 [19647066.001]
  • [Cites] Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6 [19217149.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1028-37 [12006515.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):350-8 [12077264.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3456-64 [12297390.001]
  • [Cites] Virology. 2002 Sep 15;301(1):43-52 [12359445.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3676-85 [12473576.001]
  • [Cites] Vaccine. 2003 Jan 30;21(7-8):787-90 [12531360.001]
  • [Cites] Vaccine. 2003 Mar 7;21(11-12):1187-94 [12559797.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):916-26 [12712086.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2393-8 [12750257.001]
  • [Cites] Vaccine. 2003 Sep 8;21(25-26):4036-42 [12922140.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Sep;129(9):521-30 [12898233.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2970-6 [12960321.001]
  • [Cites] Methods. 2003 Nov;31(3):225-31 [14511955.001]
  • [Cites] Mol Ther. 2003 Oct;8(4):559-66 [14529828.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):161-7 [14654953.001]
  • [Cites] Vaccine. 2004 Jan 2;22(3-4):520-7 [14670335.001]
  • (PMID = 20123582.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114425; United States / NCI NIH HHS / CA / P50 CA098252; United States / NCI NIH HHS / CA / 1R01 CA118790; United States / NCI NIH HHS / CA / R01 CA114425-05; United States / NCI NIH HHS / CA / R01 CA118790; United States / NCI NIH HHS / CA / P50 CA098252-05; United States / NCI NIH HHS / CA / 1R01 CA114425-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 161
  • [Other-IDs] NLM/ NIHMS220701; NLM/ PMC2908016
  •  go-up   go-down


71. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J: Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. Sex Transm Infect; 2009 Dec;85(7):503-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand.
  • OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM).
  • METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008.
  • Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL).
  • Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5).
  • In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL.
  • Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL.
  • Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Seronegativity / physiology. HIV Seropositivity / epidemiology. Homosexuality, Male / statistics & numerical data

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Int J STD AIDS. 2008 Aug;19(8):529-32 [18663038.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):367-73 [12626913.001]
  • [Cites] Am J Epidemiol. 2003 Jun 1;157(11):966-72 [12777359.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Arch Sex Behav. 2004 Apr;33(2):137-47 [15146146.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Aug 11;55(31):844-8 [16902394.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Sex Transm Dis. 2008 Aug;35(8):721-4 [18650771.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • (PMID = 19525263.001).
  • [ISSN] 1472-3263
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050410; United States / NCRR NIH HHS / RR / TL1 RR024978
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS527353; NLM/ PMC3875384
  •  go-up   go-down


73. Fradet-Turcotte A, Archambault J: Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther; 2007;12(4):431-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers.
  • The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers.
  • Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668552.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] ENG
  • [Grant] None / None / / 68885-1; Canada / Canadian Institutes of Health Research / / 68885-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Proteins; 0 / Viral Proteins
  • [Number-of-references] 192
  • [Other-IDs] NLM/ CAMS5300; NLM/ PMC4646640
  •  go-up   go-down


74. Engstrom PF, Arnoletti JP, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN: NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw; 2010 Jan;8(1):106-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCCN clinical practice guidelines in oncology. Anal carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064293.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


75. Fagan SP, Bellows CF 3rd, Albo D, Rodriquez-Barradas M, Feanny M, Awad SS, Berger DH: Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. Am J Surg; 2005 Nov;190(5):732-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma.
  • BACKGROUND: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV).
  • We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma.
  • METHODS: HIV-positive patients diagnosed with anal neoplasms were reviewed.
  • RESULTS: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2).
  • There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 +/- 48.5 vs. 274.7 +/- 92.0 cell/c microl; P = .94) and viral loads (19,243 +/- 18,034 vs. 67,140 +/- 39,570 RNA/mL; P = .29) between groups 1 and 2, respectively.
  • CONCLUSIONS: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease.
  • As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma / etiology. HIV. HIV Infections / complications. Immune Tolerance / physiology


76. Puglisi M, Varaldo E, Assalino M, Ansaldo G, Torre G, Borgonovo G: Anal metastasis from recurrent breast lobular carcinoma: a case report. World J Gastroenterol; 2009 Mar 21;15(11):1388-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal metastasis from recurrent breast lobular carcinoma: a case report.
  • We report a case of isolated gastrointestinal metastasis from breast lobular carcinoma, which mimicked primary anal cancer.
  • In July 2000, an 88-year-old woman presented with infiltrating lobular cancer (pT1/G2/N2).
  • Four years later, she presented with an anal polypoid lesion.
  • [MeSH-major] Anus Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Surgery. 1993 Oct;114(4):637-41; discussion 641-2 [8211676.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1745-50 [16721370.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):453-5 [11289296.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):71-3 [12488295.001]
  • [Cites] Ann Chir. 1983 May;37(4):281-4 [6625502.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):307-10 [3954484.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Tech Coloproctol. 2005 Dec;9(3):237-8 [16328121.001]
  • (PMID = 19294770.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2658842
  •  go-up   go-down


77. Shiels MS, Pfeiffer RM, Engels EA: Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med; 2010 Oct 5;153(7):452-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age at cancer diagnosis among persons with AIDS in the United States.
  • BACKGROUND: Studies have reported young ages at cancer diagnosis in HIV-infected persons and have suggested that HIV accelerates carcinogenesis.
  • OBJECTIVE: To compare ages at diagnosis for non-AIDS-defining types of cancer that occur in both the AIDS and general populations, after adjustment for differences in age and other demographic characteristics between these populations.
  • SETTING: 15 HIV/AIDS and cancer registry databases in the United States.
  • HIV/AIDS Cancer Match Study from 1996 to 2007.
  • MEASUREMENTS: Comparison of age-at-diagnosis distributions for various types of cancer in both the AIDS and general populations, after adjustment for age and other demographic characteristics.
  • Reflecting this difference, the ages at diagnosis for most types of cancer were approximately 20 years younger among persons with AIDS.
  • However, after adjustment for differences in the populations at risk, the median ages at diagnosis in the AIDS and general populations did not differ for most types of cancer (for example, colon, prostate, or breast cancer; all P > 0.100).
  • In contrast, ages at diagnosis of lung (median, 50 vs. 54 years) and anal cancer (median, 42 vs. 45 years) were significantly younger in persons with AIDS than expected in the general population (P < 0.001), and the age at diagnosis of Hodgkin lymphoma was significantly older (median, 42 vs. 40 years; P < 0.001).
  • LIMITATIONS: Information on other cancer risk factors, including cigarette smoking, was not available.
  • CONCLUSION: For most types of cancer, the age at diagnosis is similar in the AIDS and general populations, after adjustment for the ages of the populations at risk.
  • Modest age differences remained for a few types of cancer, which may indicate either acceleration of carcinogenesis by HIV or earlier exposure to cancer risk factors.
  • PRIMARY FUNDING SOURCE: National Cancer Institute.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Neoplasms / diagnosis. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age of Onset. Aged. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Anus Neoplasms / epidemiology. Female. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Humans. Incidence. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Lung Neoplasms / epidemiology. Male. Middle Aged. Registries. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Jun 1;347(9014):1551; author reply 1551-2 [8684118.001]
  • [Cites] Lancet. 1996 Mar 23;347(9004):798-800 [8622336.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Gut. 1998 Feb;42(2):170-4 [9536939.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1531-8 [16847408.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS Patient Care STDS. 2007;21 Suppl 1:S3-8 [17563287.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):150-8 [18627664.001]
  • [Cites] Clin Infect Dis. 2008 Aug 15;47(4):542-53 [18627268.001]
  • [Cites] J Gen Intern Med. 2008 Sep;23(9):1452-7 [18618198.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Jun;9(3):206-16 [19525189.001]
  • [Cites] MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166 [19730409.001]
  • [Cites] Clin Colorectal Cancer. 2009 Oct;8(4):215-9 [19822512.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):535-43 [19926961.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1068-71 [9278642.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):589-92 [12708903.001]
  • [Cites] Ann Intern Med. 2001 Jun 19;134(12):1124-9 [11412053.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [CommentIn] Ann Intern Med. 2011 May 3;154(9):642; author reply 643 [21536943.001]
  • [CommentIn] Ann Intern Med. 2011 May 3;154(9):642-3; author reply 643 [21536942.001]
  • [CommentIn] Ann Intern Med. 2010 Oct 5;153(7):477-9 [20921548.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2010 Oct 5;153(7):I48 [20921539.001]
  • (PMID = 20921544.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS231323; NLM/ PMC3071616
  •  go-up   go-down


78. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G: Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess; 2010 Nov;14(53):iii-iv, ix-x, 1-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.
  • BACKGROUND: Anal cancer is uncommon and predominantly a disease of the elderly.
  • Individuals who are human immunodeficiency virus (HIV)-positive are particularly vulnerable to HPV infections, and increasing numbers from this population present with anal cancer.
  • OBJECTIVE: To estimate the cost-effectiveness of screening for anal cancer in the high-risk HIV-positive population [in particular, men who have sex with men (MSM), who have been identified as being at greater risk of the disease] by developing a model that incorporates the national screening guidelines criteria.
  • Papers that met the inclusion criteria contained the following: data on population incidence, effectiveness of screening, health outcomes or screening and/or treatment costs; defined suitable screening technologies; prospectively evaluated tests to detect anal cancer.
  • RESULTS: The reference case cost-effectiveness model for MSM found that screening for anal cancer is very unlikely to be cost-effective.
  • The negative aspects of screening included utility decrements associated with false-positive results and with treatment for high-grade anal intraepithelial neoplasia (HG-AIN).
  • However, combined with higher regression rates from low-grade anal intraepithelial neoplasia (LG-AIN), the lowest expected incremental cost-effectiveness ratio remained at over 44,000 pounds per quality-adjusted life-year (QALY) gained.
  • LIMITATIONS: Limited knowledge is available about the epidemiology and natural history of anal cancer, along with a paucity of good-quality evidence concerning the effectiveness of screening.
  • Further studies could assess whether the screening model has underestimated the impact of anal cancer, the results of which may justify an evaluative study of the effects of treatment for HG-AIN.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / economics. HIV Infections / complications. Homosexuality, Male / statistics & numerical data. Mass Screening / economics


80. Contu SS, Agnes G, Damin AP, Contu PC, Rosito MA, Alexandre CO, Damin DC: Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. World J Gastroenterol; 2009 Sep 28;15(36):4566-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of correlation between p53 codon 72 polymorphism and anal cancer risk.
  • AIM: To investigate the potential role of p53 codon 72 polymorphism as a risk factor for development of anal cancer.
  • METHODS: Thirty-two patients with invasive anal carcinoma and 103 healthy blood donors were included in the study. p53 codon 72 polymorphism was analyzed in blood samples through polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing.
  • RESULTS: The relative frequency of each allele was 0.60 for Arg and 0.40 for Pro in patients with anal cancer, and 0.61 for Arg and 0.39 for Pro in normal controls.
  • CONCLUSION: These results do not support a role for the p53 codon 72 polymorphism in anal carcinogenesis.
  • [MeSH-major] Anus Neoplasms / genetics. Genes, p53

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):444-61 [10873790.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):565-6 [11352871.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):782-6 [11787851.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):175-83 [11888672.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Am J Hum Biol. 2003 Nov-Dec;15(6):824-34 [14595874.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):131-5 [14734461.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):11-22 [14744727.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jun;85(3):301-8 [15145278.001]
  • [Cites] Mol Cell Biol. 1986 Dec;6(12):4650-6 [3025664.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Nucleic Acids Res. 1990 Aug 25;18(16):4961 [1975675.001]
  • [Cites] Hum Hered. 1994 Sep-Oct;44(5):266-70 [7927355.001]
  • [Cites] Hum Hered. 1995 May-Jun;45(3):144-9 [7615299.001]
  • [Cites] Hum Hered. 1996 Jan-Feb;46(1):41-8 [8825462.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] J Mol Med (Berl). 1999 Feb;77(2):299-302 [10023783.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):143-7 [15899386.001]
  • [Cites] Am J Hum Biol. 2005 Jul-Aug;17(4):496-506 [15981186.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):523-9 [17113725.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Eur J Surg Oncol. 2007 Jun;33(5):569-74 [17321098.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):621-32 [17405118.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):798-804 [18234542.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):809-14 [19212643.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92 [11032762.001]
  • (PMID = 19777616.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon
  • [Other-IDs] NLM/ PMC2752002
  •  go-up   go-down


81. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


82. Garland SM: Prevention strategies against human papillomavirus in males. Gynecol Oncol; 2010 May;117(2 Suppl):S20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogenic HPV is strongly associated with cancers and high-grade dysplasias of the anogenital tract, including the anus, penis, and also a proportion of oropharyngeal cancers.
  • In reducing male disease burden, some consider screening and treatment for high-grade anal dysplasia (AIN) to prevent anal cancer in high-risk populations.
  • Such a vaccination strategy including 12-year-old boys is projected by 2050 to reduce HPV 16 infection by 88-94% in females and 68-82% in males, plus the aforementioned male HPV- related cancers by 22-27%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 20138347.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


83. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H: Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis; 2005 May;32(5):314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy.
  • OBJECTIVE: We sought to determine if the introduction of highly active antiretroviral therapy (HAART) corresponded with changes in anal squamous cell cancer rates among men with AIDS.
  • STUDY: We linked cancer registry data from 1988-2000 and AIDS registry data from 1981-July/2003 for San Diego County.
  • RESULTS: The annual incidence of invasive anal cancer increased from zero per 100,000 men with AIDS aged 25 to 64 years (95% confidence interval [CI], 0-226) in 1991 to 224 per 100,000 (95% CI, 102-425) in the year 2000.
  • Pre-HAART, the average annual incidence of invasive anal cancer was 49 per 100,000 men with AIDS aged 25 to 64 years (95% CI, 16-114) versus 144 per 100,000 (95% CI, 93-212) post-HAART.
  • The relative risk of invasive anal cancer among men with AIDS compared with men without known HIV/AIDS was 98 (95% CI, 36-264) pre-HAART and 352 (95% CI, 186-669) post-HAART.
  • The increased incidence of anal cancer among men with AIDS resulted in an increase in the overall rate of anal cancer among men in San Diego County.
  • CONCLUSIONS: The rising incidence of anal cancer among men with AIDS may be related to increased longevity with HAART and the consequent increased time at risk for the development of malignancy and/or the result of greater use of cytologic screening.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology


84. Cotte E, Lifante JC, Cherki S, François Y, Vignal J, Peix JL, Glehen O: [Rectal amputation by pure perineal approach with laparoscopic colostomy: a palliative therapeutic option for low rectal or anal cancers for elderly patients with multiple comorbidities]. Ann Chir; 2006 Feb;131(2):100-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal amputation by pure perineal approach with laparoscopic colostomy: a palliative therapeutic option for low rectal or anal cancers for elderly patients with multiple comorbidities].
  • [Transliterated title] Amputation du rectum par voie périnéale pure avec colostomie coelio-assistée: une option thérapeutique palliative pour les cancers du bas rectum ou de l'anus chez le sujet âgé ou multitaré.
  • Rectal syndrome caused by locoregional evolution of low rectal cancers and anal cancers is prevented and treated by surgical resection.
  • The palliative treatment of low rectal cancers or anal cancers combining rectal amputation by pure perineal approach with laparoscopic colostomy may be an interesting therapeutic option for patients who cannot undergoing aggressive carcinologic surgical treatment.
  • [MeSH-major] Anus Neoplasms / surgery. Colostomy / methods. Laparoscopy. Palliative Care. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430855.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


85. Membrilla-Fernández E, Parés D, Alameda F, Pascual M, Courtier R, Gil MJ, Vallecillo G, Fusté P, Pera M, Grande L: [Anal intraepithelial neoplasia: application of a diagnostic protocol in risk patients using anal cytology]. Cir Esp; 2009 Jun;85(6):365-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia: application of a diagnostic protocol in risk patients using anal cytology].
  • [Transliterated title] Neoplasia intraepitelial anal: resultados de la aplicación de un protocolo diagnóstico en pacientes de riesgo mediante el uso de citología anal.
  • INTRODUCTION: Anal intraepithelial neoplasia is a precursor condition of squamous anal carcinoma.
  • The aim of this study was to analyse the results of a diagnostics protocol of Anal Intraepithelial Neoplasia in high risk population using anal cytology.
  • PATIENTS AND METHOD: The protocol is based on a visit in the outpatient department, clinical interview, physical examination and anal cytology evaluated by Bethesda criteria.
  • The cross-sectional observational study was designed to study the anal smear results and their relationship with risk factors.
  • In the overall series, 25 patients have been diagnosed with abnormal anal cytology: 9 atypical squamous cells of undetermined significance (ASCUS), 15 low-grade and 1 high-grade squamous intraepithelial lesions.
  • There were no significant associations between abnormal cytology results and the presence of anal condyloma (p = 0.22).
  • CONCLUSIONS: Our diagnostic protocol of anal intraepithelial neoplasia revealed 25% of patients with pre-invasive lesions of squamous anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303590.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Siekas LL, Aboulafia DM: Establishing an anal dysplasia clinic for HIV-infected men: initial experience. AIDS Read; 2009 May;19(5):178-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing an anal dysplasia clinic for HIV-infected men: initial experience.
  • Anal dysplasia caused by human papillomavirus (HPV) infection is common in the HIV-infected population and is a precursor to squamous cell carcinoma of the anus (SCCA).
  • Herein, we describe our initial experience in assessing the frequency and severity of anal intraepithelial neoplasia (AIN) in a newly formed anal dysplasia clinic in Seattle.
  • We anticipate that the anal dysplasia clinic will enable our institution to participate in emerging HIV- and HPV-related AIN clinical trials.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / etiology. HIV Infections / epidemiology. Precancerous Conditions / etiology


87. Moreau MV, Tournier-Rangeard L, Kaminsky MC, Peiffert D: [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer]. Cancer Radiother; 2009 Jul;13(4):329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer].
  • [Transliterated title] Chimioradiothérapie de rattrapage pour métastases médiastinales et pleuropulmonaires d'un cancer du canal anal.
  • This case report presents a 57 years-old woman treated for a squamous cell carcinoma of the anal canal by radiochemotherapy and brachytherapy.
  • This observation is interesting for its curative treatment in metastatic cancer of the anal canal.
  • It also illustrates the radiosensibility of anal canal cancers, including metastatic situations, and raises the contribution of PET-scanner to evaluate the response to treatment and detect a recurrence.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell / secondary. Mediastinal Neoplasms / secondary. Pleural Neoplasms / secondary. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467897.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Felt-Bersma RJ, Cazemier M: Endosonography in anorectal disease: an overview. Scand J Gastroenterol Suppl; 2006;(243):165-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was first used to evaluate rectal tumours and later also to investigate benign disorders of the anal sphincters and pelvic floor.
  • AE has been used for almost every possible disorder in the anal region and has increased our insight into anal pathology.
  • Studies comparing AE with endoanal magnetic resonance imaging (MRI) have shown that both methods are equally good for demonstrating defects in the external anal sphincter; the internal anal sphincter is better visualized with AE.
  • 4. Anal carcinoma for staging.
  • In conclusion, AE images the internal and external anal sphincter with high accuracy.
  • It is easy to perform and is of particular value in the diagnosis of anal incontinence and perianal fistulae.
  • It is excellent in staging anal carcinoma and can also be used in staging rectal carcinoma, especially very low large malignant polyps.
  • [MeSH-major] Anus Diseases / ultrasonography. Endosonography. Rectal Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782637.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 119
  •  go-up   go-down


89. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Karaitianos IG, Archondakis SK, Korkolis D, Koundouris C, Xenitidis M, Daskalopoulou D, Tsigris C: The role of cytology in the diagnosis of benign and malignant anal lesions. Acta Chir Iugosl; 2006;53(2):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytology in the diagnosis of benign and malignant anal lesions.
  • Squamous cell carcinoma is a rather infrequent neoplasm of the gastrointestinal tract.
  • Squamous cell carcinoma is a slowly and locally growing neoplasm which metastasizes in advanced stages.
  • Its diagnosis must be accomplished by the least traumatic examinations possible.
  • In 89 of them cytological material from ulcerated positions of the anal region was examined.
  • In the rest 27 cytological material was obtained by fine needle aspiration of subcutaneous or submucosal anal lesions.
  • Cytological evaluation revealed 29 cases of normal anal epithelium, 13 granulomas, 12 cases of HPV infection, 28 anal squamous intraepithelial lesions (ASIL), 17 post radiation injuri-es of the anal mucosa and 17 carcinomas.
  • The neoplasms were further subclassified in 12 well differentiated squamous cell carcinomas, 4 cloacogenic carcinomas and 1 leiomyosarcoma.
  • Histological examination followed the initial cytological diagnosis in 75 cases.
  • It is well accepted by the patients and of paramount clinical utility for the initial diagnostic assessment, the long-term follow up after treatment of anal cancer patients.
  • It is also valuable for the differential diagnosis among benign, premalignant and malignant anal lesions.
  • [MeSH-major] Anus Diseases / diagnosis. Anus Neoplasms / diagnosis. Biopsy, Needle
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / diagnosis. Cytodiagnosis. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139883.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


91. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK, Infectious Disease Clinical Research Program HIV Working Group: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS; 2010 Feb 20;24(4):535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.
  • OBJECTIVE: To evaluate the incidence rates of anal cancer over the HIV epidemic and assess the impact of HAART use on anal cancer events.
  • METHODS: We evaluated the incidence of and factors associated with anal cancer using longitudinal data from the prospective U.S.
  • RESULTS: Among 4506 HIV-infected men with 37 806 person-years of follow-up, anal cancer rates (per 100 000 person-years) increased five-fold, from 11 in the pre-HAART to 55 in the HAART era (P = 0.02).
  • At cancer diagnosis (n = 19), median age was 42 years, median CD4 cell count was 432 cells/microl, 74% had a CD4 nadir cell count less than 200 cells/microl, 42% had a prior AIDS event, and 74% had received HAART.
  • From separate models, prior AIDS event (hazard ratio 3.88, P = 0.01) and lower CD4 nadir (hazard ratio 0.85 per 50 cell, P = 0.03) were associated with anal cancer, with a trend for a history of gonorrhea (hazard ratio 2.43, P = 0.07).
  • Duration of HAART use was not associated with a reduced risk of anal cancer (hazard ratio 0.94, P = 0.42).
  • CONCLUSION: Incidence rates of anal cancer have progressively increased during the HIV epidemic.
  • Persons with a longer duration of HIV infection have a substantially higher rate of anal cancer.
  • As HIV-infected persons are experiencing longer life expectancies and HAART does not appear protective of anal cancer, studies on preventive strategies are needed.